GB2109796A - Anorexigenic tripeptides, process for the preparation thereof and pharmaceutical compositions containing them - Google Patents
Anorexigenic tripeptides, process for the preparation thereof and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- GB2109796A GB2109796A GB08227888A GB8227888A GB2109796A GB 2109796 A GB2109796 A GB 2109796A GB 08227888 A GB08227888 A GB 08227888A GB 8227888 A GB8227888 A GB 8227888A GB 2109796 A GB2109796 A GB 2109796A
- Authority
- GB
- United Kingdom
- Prior art keywords
- pro
- formula
- tripeptide
- tripeptides
- protected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 17
- 230000002891 anorexigenic effect Effects 0.000 title claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 239000002253 acid Substances 0.000 claims abstract description 9
- 125000006239 protecting group Chemical group 0.000 claims abstract description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 8
- 150000001413 amino acids Chemical class 0.000 claims abstract description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 230000008878 coupling Effects 0.000 claims abstract 2
- 238000010168 coupling process Methods 0.000 claims abstract 2
- 238000005859 coupling reaction Methods 0.000 claims abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 108010016626 Dipeptides Proteins 0.000 claims description 5
- 150000004702 methyl esters Chemical class 0.000 claims description 3
- GXRIHBFYWAYOGB-JTQLQIEISA-N 1-O-benzyl 2-O-(2,3,4,5,6-pentafluorophenyl) (2S)-5-oxopyrrolidine-1,2-dicarboxylate Chemical compound FC1=C(C(=C(C(=C1OC([C@H]1N(C(CC1)=O)C(=O)OCC1=CC=CC=C1)=O)F)F)F)F GXRIHBFYWAYOGB-JTQLQIEISA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- BLWYXBNNBYXPPL-YFKPBYRVSA-N methyl (2s)-pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCN1 BLWYXBNNBYXPPL-YFKPBYRVSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims 1
- 239000012059 conventional drug carrier Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 229940086542 triethylamine Drugs 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229960002429 proline Drugs 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- QWCKQJZIFLGMSD-VKHMYHEASA-N L-alpha-aminobutyric acid Chemical compound CC[C@H](N)C(O)=O QWCKQJZIFLGMSD-VKHMYHEASA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- CJUMAFVKTCBCJK-UHFFFAOYSA-N N-benzyloxycarbonylglycine Chemical compound OC(=O)CNC(=O)OCC1=CC=CC=C1 CJUMAFVKTCBCJK-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 3
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 3
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- DZLNHFMRPBPULJ-GSVOUGTGSA-N D-thioproline Chemical compound OC(=O)[C@H]1CSCN1 DZLNHFMRPBPULJ-GSVOUGTGSA-N 0.000 description 2
- VTJUNIYRYIAIHF-IUCAKERBSA-N Leu-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O VTJUNIYRYIAIHF-IUCAKERBSA-N 0.000 description 2
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- ORQXBVXKBGUSBA-QMMMGPOBSA-N β-cyclohexyl-alanine Chemical compound OC(=O)[C@@H](N)CC1CCCCC1 ORQXBVXKBGUSBA-QMMMGPOBSA-N 0.000 description 2
- IWCSBUBELIDSKW-RYUDHWBXSA-N (2s)-1-[(2s)-4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O IWCSBUBELIDSKW-RYUDHWBXSA-N 0.000 description 1
- CKGCFBNYQJDIGS-LBPRGKRZSA-N (2s)-2-azaniumyl-6-(phenylmethoxycarbonylamino)hexanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])CCCCNC(=O)OCC1=CC=CC=C1 CKGCFBNYQJDIGS-LBPRGKRZSA-N 0.000 description 1
- ONOURAAVVKGJNM-SCZZXKLOSA-N (2s,3r)-2-azaniumyl-3-phenylmethoxybutanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](C)OCC1=CC=CC=C1 ONOURAAVVKGJNM-SCZZXKLOSA-N 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- VVCLBQFBKZQOAF-NSHDSACASA-N benzyl (2s)-pyrrolidine-2-carboxylate Chemical compound O=C([C@H]1NCCC1)OCC1=CC=CC=C1 VVCLBQFBKZQOAF-NSHDSACASA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- -1 benzyloxycarbonyl-L-pyroglutamic acid pentafluorophenyl ester Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- RQWCWDUGWXKMEV-STQMWFEESA-N methyl (2S)-1-[(2S)-4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)OC(C)(C)C RQWCWDUGWXKMEV-STQMWFEESA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0825—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Glp-amino acid; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Tripeptides having anorexigenic activity of the formula (I): X-Y-Pro-OH (I> in which X is Glp, Kic, Tca; Y is Gly, Ala, Val, Ile, Pro, Abu, Nva, Nle Ada, Cha, Phe, Trp, Tyr, Ser, Thr, Met, Gln, Lys, Arg, Leu, and acid addition salts and complexes thereof. The tripeptides are prepared by coupling proline or a carboxyl- protected derivative thereof with the amino acids X and Y or protected derivatives thereof by known methods of peptide chemistry, with the consequential removal of protecting group(s) if present. There are also provided pharmaceutical compositions having anorexigenic activity, which comprise, as the active ingredient, tripeptides of the formula (I), pharmaceutically acceptable acid addition salts or complexes thereof.
Description
SPECIFICATION
Anorexigenic tripeptides, process for the preparation thereof and pharmaceutical compositions containing them
This invention relates to new tripeptides having anorexigenic activity, a process for their preparation and pharmaceutical compositions containing them.
More particularly, the invention provides new tripeptides of the formula (I):
X-Y-Pro-OH (I) in which Xis Glp, Kic orTca;
Y is Giy, Ala, Val, lle, Pro, Abu, Nva, Nle, Ada, Cha, Phe, Trp, Tyr, Ser, Thr, Met, Gin, Lys, Arg or
Leu, and acid addition salts and complexes thereof.
According to another aspect of the invention, there is provided a process for the preparation of the tripeptides of the formula (I) and acid addition salts and complexes thereof.
The invention further provides new pharmaceutical compositions having anorexigenic activity, which comprise compounds of the formula (I) or pharmaceutically acceptable salts or complexes thereof as an active ingredient.
Reichelt et al. [Neuroscience 3, 1 207 (1 978)] isolated a Glp-His-Gly-OH tripeptide from the urine of patients suffering from anorexia nervosa. The tripeptide showed anorexigenic activity in animal tests.
This experimental result was an important contribution to the earlier assumption that certain peptides may play an essential role in the so far unknown mechanism of the development of the sensation of hunger and repletion, respectively. Taking into account the structural similarities between the above tripeptide and TRH (thyrotropin-releasing hormone) (Glp-His-Pro-NH2) it may well be assumed that both peptides are formed from the same precursor molecule.
We have found that a precondition of the anorexigenic activity is the presence of a free carboxyl group at the C-terminal moiety since the compounds containing a C-terminal carboxamido group showed no anorexigenic activity. We have further found that the presence of histidine in the centre of the molecule is not essential. The compounds in which the central amino acid has an aliphatic sidechain and the C-terminal amino acid is a free carboxyl-containing proline proved to be the most effective.
The compounds of the formula (I):
X-Y-Pro-OH (I) in which X and Y have the same meaning as defined above, can be prepared by any method conventionally used in the chemistry of peptides. Preferably, the amino acids X and Y or protected derivatives thereof are coupled to the proline or a carboxyl-protected derivative thereof by a conventional technique of peptide chemistry, and, if the tripeptides are obtained in a protected form the protecting groups are eliminated therefrom in a known manner.
According to a preferred embodiment of this process, proline methyl ester is acylated by a protected amino acid tert.-butyloxycarbonyl-Y-OH, the dipeptide methyl ester obtained is saponified with a dioxanic sodium hydroxide solution and the tert-butyloxycarbonyl protecting group is eliminated by treatment with hydrochloric acid/ethyl acetate. The Y-Pro-CH.HCI dipeptide salt is then acylated with benzyloxycarbonyl-pyroglutamic acid pentafluorophenyl ester, and the benzyloxy group is eliminated from the protected tripeptide by catalytic hydrogenolysis.
The compounds of the formula (I) can be purified by conventional purification techniques, preferably column chromatography or by precipitation from a suitable solvent. The compounds are obtained as lyophilized powders or solid powders, which can be formulated into various pharmaceutical preparations.
The anorexigenic activity of the compounds of the formula (I) was tested on rats. The food consumption of test animals starved for 96 hours was measured one and five hours after the intracerebroventicular (icv.) administration of a physiological saline solution (control) and the test materials, respectively. The corresponding data for certain compounds according to the invention, TRH and the tripeptide Glp-His-Gly-OH are set forth in the following Table 1.
Table 1
Food consump Time of food tion (g) in 24 administration hours of rats Dose after injection Route of starved for (,ng) (hours) adminstration 96 hours Control 5 5 icv. 22.16+0.88 Glp-His-Pro-NH2 300 1 icv. 19.8111.52 300 5 icv. 17.88+2.94 Glp-His-Gly-OH 300 1 icv. 19.33+1.08 300 5 icv. 18.38F1.80 Glp-Leu-Pro-OH 300 1 icv. 6.101.99 5 icv. 9.23+0.92 Glp-Abu-Pro-OH 300 5 icv. 8.31 11.50 The data clearly show that neither THR nor Glp-His-Gly-OH reduced substantially the food consumption of the test animals under the given test conditions, unlike the tested representatives of the compounds of the formula (I) which results in a significant decrease of food uptake.
The peptides according to the invention, their salts and complexes are used in the therapy as pharmaceutical compositions. These compositions comprise the compounds according to the invention in association with conventional, pharmaceutically acceptable inorganic or organic carriers or excipients suitable for enteral or parenteral administration. Solid lyophilizates may also be prepared, in which materials inert to the peptides, e.g. carbohydrates, are generally used as carriers. Further pharmaceutical formulations include dilute or concentrated suspensions and emulsions which may also contain various preserving and stabilizing additives.
The invention will be illustrated in greater detail in two general Examples which are given for illustration and not limitation of our invention. The compounds prepared by one of the illustrated methods together with their physical constants are given in Table 2.
The abbreviations used in the Examples and throughout the specification are internationally accepted designations [J. Biol. Chem. 247, 977 (1972)]. Further abbreviations:
Abu=L-2-aminobutyric acid; Ada=L-2-aminodecanic acid;
Cha=L-cyclohexylalanine; Kic=L-2-keto-imidazolidine-4-carboxylic acid;
Tca=L-thiazolidine-4-carboxylic acid.
Evaporation was aiways carried out in a Büchi Rotavapor "R" equipment. Melting points were determined in an apparatus by Dr. Tottoli (Bijchi). The thin-layer chromatograms were prepared on "Kieselgel G" (Merck) silicagel phases according to Stahl. For preparing the chromatograms the following solvent mixtures were used:
(1) 3:2 mixture of ethyl acetate and PAW
(2) 1:1 mixture of ethyl acetate and PAW
(3) 3:1:1 mixture of n-butanol, acetic acid and water PAW=20:6:1 1 mixture of pyridine, acetic
acid and water.
The thin layer chromatograms were developed by ninhydrin or by a tolidine/potassium iodide spray, after chlorination.
Certain compounds were purified on a column filled with "Kieselgel G" silica gel having a grain size of 0.062 to 0.2 mm.
Example 1 L-Pyroglutamyl-L-leucyl-L-proline (method "A")
Step 1
L-Leucyl-L-proline.HCI
5.5 g (33 mmoles) of Pro-OMe.HCI are dissolved in 80 ml of dichloromethane, the solution is cooled to OOC and 4.52 ml (33 mmoles) of triethyl amine and subsequently 6.93 g (30 mmoles) of
Boc-Leu-OH are added with stirring. As soon as the reactants are dissolved, a solution of 6.18 g (30 mmoles) of dicyclohexyl carbodiimide in 40 ml of dichloromethane is added, whereupon the reaction mixture is stirred at 0 C for 2 hours and the dicyclohexyl carbodiimide is filtered off. The filtrate is shaken with three 30-ml portions of a 1 N hydrochloric acid solution, three 30-ml portions of a 1 N sodium hydrogen carbonate solution and 30 ml of water.The dichloromethane solution is dried with anhydrous sodium sulphate and evaporated. 9.7 9 of Boc-Leu-Pro-OMe are obtained as an oily product. The product is dissolved in 43 ml of dioxane, and 43 ml of a 1 N sodium hydroxide solution are added with stirring. The reaction mixture is stirred at room temperature for one hour and neutralized with a 1 N hydrochloric acid solution. Dioxane is distilled off and the pH of the aqueous solution obtained is adjusted to 2 by adding 60 ml of chloroform and concentrated sulphuric acid. After separation the aqueous solution is shaken with a further two 30-ml portions of chloroform. The combined chloroform solution is shaken with water and dried over anhydrous sodium sulphate.The solvent is eliminated, the residual 9 g of Boc-Leu-Pro-OH are dissolved in 25 ml of ethyl acetate and 25 ml of a 5 N solution of hydrochloric acid in ethyl acetate are added to the solution. The reaction mixture is allowed to stand at room temperature for one hour, diluted with ether and the precipitated substance is filtered off, washed with ether and dried. 6.48 9 (81.5% reiated to Boc-Leu-OH) of H-Leu-Pro
OH.HCI are obtained. The product is a chromatographically uniform, white, hydroscopic material.
Rf2=0.20; Rf3=0.41.
Step 2 Benzyloxyearbonyl-L-pyroglutamyl-L-leucyl-L-proline 2.09 g (7.87 mmoles) of H-Leu-Pro-OH. HCI, 2.2 ml of triethyl amine and 3.38 g (7.87 mmoles) of benzyloxycarbonyl-L-pyroglutamic acid pentafluorophenyl ester are dissolved in 50 ml of chloroform. After standing for 10 minutes 1.1 ml (7.87 mmoles) of triethyl amine are added and the solution is aliowed to stand overnight at room temperature. Thereafter, the reaction mixture is shaken with three 10-ml portions of a 1 N hydrochloric acid solution and two 10-ml portions of water, dried with anhydrous sodium sulphate and evaporated.Crystallization of the oily evaporation residue from ether affords 3.15 g of a crude product which is then recrystallized from 10 ml of ethyl acetate. 2.7 g (73.5%) of chromatographically uniform Z-Glp-Leu-Pro-OH are obtained, melting at 98 to 1000C.
Step 3
4.13 g (8.7 mmoles) of Z-Glp-Leu-Pro-OH are dissolved in 80 ml of ethanol, 0.8 g of a 10% palladium-on-charcoal catalyst are added and hydrogen gas is bubbled through the solution for one hour. The catalyst is filtered off, the filtrate is evaporated and the amorphous residue is triturated with ether and filtered off. 2.8 g of a crude product are obtained, which are then dissolved in 20 ml of water, decoloured with charcoal and the solution is lyophilized. 2.6 g (91%) of amorphous, chromatographically uniform Glp-Leu-Pro-OH are obtained. Rf1=0.33.
Example 2
L-Pyroglutamyl-glicyl-L-proline (method "B")
Step 1
Glicyl-L-proline
5.33 g (22 mmoles) of H-Pro-OBzl- HCI and 4.2 g (20 mmoles) of Z-Gly-OH are dissolved in 50 ml of dichloromethane, 3.08 ml of triethyl amine are added to the solution, it is cooled at OOC and a solution of 4.12 g (20 mmoles) of dicyclohexyl carbodiimide in 30 ml of dichloromethane is added. The reaction mixture is then stirred for one hour at OOC and kept in a refrigerator overnight. Dicyclohexyl carbodiimide is filtered off and the filtrate is extracted with two 30-ml portions of a 1 N hydrochloric acid solution, two 30-ml portions of a 1 N sodium hydrogen carbonate solution and 30 ml of water.
The dichloromethane solution is dried with anhydrous sodium sulphate and evaporated. 8.5 g of Z-Gly
Pro-OBzl are obtained as an oily substance, which is dissolved in 1 70 ml of ethanol, 1.5 g of a 10% palladium-on charcoal catalyst are added and hydrogen is bubbled through the solution.When the reaction is complete, the reaction mixture is diluted with 100 ml of water, the catalyst is filtered off, washed with water and the filtrate is evaporated. 2.12 g (62% related to Z-Gly-OH) of H-Gly-Pro-OH are obtained as a chromatographically uniform product. Ref3=0.19, Step 2 Benzyloxycarbonyl-L-pyrogluta myl-glycyl-L-prol ine
2.15 g (5 mmoles) of Z-Glp-OPfp and 0.86 g (5 mmoles) of H-Gly-Pro-OH are suspended in 20 ml of dimethyl formamide. 0.7 ml of triethyl amine are added to the suspension.After one hour the reaction mixture is evaporated, the residue is dissolved in 30 ml of chloroform and the solution is shaken with two 7-ml portions of a 1 N hydrochloric acid solution, two 7-ml portions of a 1 N sodium hydrogen carbonate solution and water. Upon drying the solution is evaporated. The oily residue is crystallized from ether, filtered off and the crude product, weighing 1.4 g, is recrystallized from a mixture of ethanol and ethyl acetate. 1.23 g (53%) of Z-Glp-Gly-Pro-OH are obtained as a chromatographically uniform product.
Step 3
0.35 g (0.84 mmoles) of Z-Glp-Gly-Pro-OH are dissolved in 30 ml of ethanol, 0.05 g of a 10% palladium-on-charcoal catalyst are added and hydrogen gas is bubbled through the solution. The catalyst is filtered off, the filtrate is evaporated and the residue is triturated with ether and filtered. 0.22 g of the title compound is obtained. The product is treated with ethyl acetate and filtered to yield 0.17 g (71.5%) of a chromatographically uniform, amorphous product. Rf=0.06; Rf =0.25.
The new compounds prepared according to any of the above methods are set forth in the following Table 2.
Table 2
Melting point Tripeptides Method [OC] Rf1 Rf2 Rf Glp-Ala-Pro-OH A 234-236 (decomp.) 0.12 0.31 Glp-Val-Pro-OH A amorphous 0.20 Glp-lle-Pro-OH A amorphous 0.26 Glp-Pro-P ro-OH A 188-191 (decomp.) 0.07 0.25 Glp-Abu-Pro-OH A 248-250 (decomp.) 0.11 Glp-Nva-Pro-OH A 183-186 0.19 Glp-Nle-Pro-OH A amorphous 0.26 Glp-Ada-Pro-OH A amorphous 0.35 Glp-Cha-Pro-OH A amorphous 0.30 Glp-Phe-Pro-OH A amorphous 0.22 Glp-Trp-Pro-OH A 204-206 (decomp.) 0.27 Glp-Tyr-Pro-OH(a) A 132-134 (decomp.) 0.22 Glp-Ser-Pro-OHlbl A 144-146 (decomp.) 0.07 0.25 Glp-Thr-Pro-OHtCl A 179-181 (decomp.) 0.12 0.31 Glp-Met-Pro-OH(d) A amorphous 0.22 Glp-Gln-Pro-OH(e) A amorphous 0.07 0.23 Glp-Lys-Pro-OH(fl A 165-167 (decomp.) 0.16 Glp-Arg-Pro-OH(g) A 297-298 (decomp.) 0.17 Glp-Gly-Pro-OH B amorphous 0.06 0.25 Kic-Leu-Pro-OH A amorphous 0.37 Tca-Leu-Pro-OHzh) A 1 57-1 60 0.48 Using Try(But) (h)Using Ser(Bzl) (0)Using Thr(Bzl) The Z protecting group was eliminated with TFA As a protected tripeptide purified by column chromatography
(f)Using Lys(Z)
(g)Using Arg(NO2)
(h)Using Boc-Tca
Claims (10)
1. A tdpeptide of the formula (I):
X-Y-Pro-OH (I) in which
X is Glp, Kic or Tca;
Y is Gly, Ala, Val, lle, Pro, Abu, Nva, Nile, Ada, Cha, Phe, Trp, Tyr, Ser, Thr, Met, Gln, Lys, Arg or
Leu, or an acid addition salt or complex thereof.
2. A process for preparing a tripeptide of the formula (I) as defined in claim 1, or an acid addition salt or complex thereof, which comprises coupling with proline or a carboxyl-protected derivative thereof the amino acids X and Y or protected derivatives thereof by a conventional method of peptide chemistry and splitting off the protecting groups in a known manner from the tripeptides obtained in a protected form.
3. A process as claimed in claim 2, which comprises acylating proline methyl ester with the protected amino acid tert.-butyloxywarbonyl-Y-OH, saponifying the dipeptide methyl ester obtained, eliminating the tert.-butyloxycarbonyl protecting group, and acylating the dipeptide obtained or an acid addition salt thereof with benzyloxycarbonylpyroglutamic acid pentafluorophenyl ester, and eliminating the protecting group from a protected tripeptide obtained.
4. A process as claimed in claim 3, wherein the dipeptide methyl ester is saponified with a dioxanic sodium hydroxide solution.
5. A process as claimed in claim 3 or 4, wherein the tert.-butyloxycarbonyl protecting group is eliminated by treatment with ethyl acetate.
6. A process as claimed in any of claims 3 to 5, wherein the protecting group is eliminated from the protected tripeptide by catalytic hydrogenation.
7. A pharmaceutical composition having anorexigenic activity, which comprises as an active ingredient a tripeptide of the formula (I) as defined in claim 1 , or a pharmaceutically acceptable acid addition salt or complex thereof, in association with at least one conventional pharmaceutical carrier and/or excipient and/or further conventional additive.
8. A tripeptide of the formula (I) substantially as herein described in any of the Examples.
9. A process for preparing tripeptides of the formula (I) substantially as herein described in any of the examples.
10. A tripeptide of the formula (I) whenever prepared by a process as claimed in any of claims 2 to 6 and 9.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU812861A HU184481B (en) | 1981-10-02 | 1981-10-02 | Process for producing tripeptides for diminishing appetite |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB2109796A true GB2109796A (en) | 1983-06-08 |
| GB2109796B GB2109796B (en) | 1985-01-30 |
Family
ID=10961417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB08227888A Expired GB2109796B (en) | 1981-10-02 | 1982-09-30 | Anorexigenic tripeptides, process for the preparation thereof and pharmaceutical compositions containing them |
Country Status (5)
| Country | Link |
|---|---|
| CH (1) | CH654841A5 (en) |
| DE (1) | DE3236484A1 (en) |
| FR (1) | FR2513994B1 (en) |
| GB (1) | GB2109796B (en) |
| HU (1) | HU184481B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2185483B (en) * | 1986-01-21 | 1990-10-24 | Nippon Shinyaku Co Ltd | Pyroglutamide derivatives |
| WO1996026955A1 (en) * | 1995-03-02 | 1996-09-06 | Vladislav Isakovich Deigin | Peptide and a method of obtaining it |
| WO1996040740A1 (en) * | 1995-06-07 | 1996-12-19 | Vladislav Isakovich Deigin | Peptide and method of obtaining it |
| US6159940A (en) * | 1996-02-28 | 2000-12-12 | Immunotech Developments Inc. | Method for modulating hemopoiesis |
| EP1977750A4 (en) * | 2006-01-02 | 2010-11-03 | Univ Cadiz | USE OF THIOPROLINE IN BODY WEIGHT REDUCTION TREATMENTS |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0336356A3 (en) * | 1988-04-05 | 1991-09-25 | Abbott Laboratories | Derivatives of tryptophan as cck antagonists |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2343037A1 (en) * | 1973-08-25 | 1975-03-06 | Hoechst Ag | MEDICINAL PRODUCTS WITH ANTIDEPRESSIVE EFFECT |
| US3959248A (en) * | 1974-04-03 | 1976-05-25 | Merck & Co., Inc. | Analogs of thyrotropin-releasing hormone |
| LU73294A1 (en) * | 1975-09-02 | 1977-05-11 | ||
| US4066749A (en) * | 1977-01-24 | 1978-01-03 | Merck & Co., Inc. | Tetrapeptide analog of TRH |
| HU180926B (en) * | 1979-06-28 | 1983-05-30 | Richter Gedeon Vegyeszet | Process for preparing trh analogues,tripeptide amides infectives on the central nerve sysrhem |
-
1981
- 1981-10-02 HU HU812861A patent/HU184481B/en not_active IP Right Cessation
-
1982
- 1982-09-30 GB GB08227888A patent/GB2109796B/en not_active Expired
- 1982-09-30 FR FR8216438A patent/FR2513994B1/en not_active Expired
- 1982-10-01 DE DE19823236484 patent/DE3236484A1/en not_active Withdrawn
- 1982-10-01 CH CH5796/82A patent/CH654841A5/en not_active IP Right Cessation
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2185483B (en) * | 1986-01-21 | 1990-10-24 | Nippon Shinyaku Co Ltd | Pyroglutamide derivatives |
| WO1996026955A1 (en) * | 1995-03-02 | 1996-09-06 | Vladislav Isakovich Deigin | Peptide and a method of obtaining it |
| WO1996040740A1 (en) * | 1995-06-07 | 1996-12-19 | Vladislav Isakovich Deigin | Peptide and method of obtaining it |
| US6159940A (en) * | 1996-02-28 | 2000-12-12 | Immunotech Developments Inc. | Method for modulating hemopoiesis |
| EP1977750A4 (en) * | 2006-01-02 | 2010-11-03 | Univ Cadiz | USE OF THIOPROLINE IN BODY WEIGHT REDUCTION TREATMENTS |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2513994A1 (en) | 1983-04-08 |
| HU184481B (en) | 1984-08-28 |
| GB2109796B (en) | 1985-01-30 |
| CH654841A5 (en) | 1986-03-14 |
| FR2513994B1 (en) | 1986-08-01 |
| DE3236484A1 (en) | 1983-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4024248A (en) | Peptides having LH-RH/FSH-RH activity | |
| NO139560B (en) | ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY EFFECTIVE NONAPEPTIDAMIDE DERIVATIVES | |
| CS199673B2 (en) | Method of producing polypeptides | |
| HU205142B (en) | Process for producing peptides having t cell helper activity and pharmaceutical compositions comprising same | |
| US4386073A (en) | Tripeptides acting on the central nervous system and a process for the preparation thereof | |
| US3842064A (en) | Psychopharmacologically active tetra-,penta-,hexa-,and hepta-peptides | |
| US4703034A (en) | Novel cyclic tetrapeptide | |
| EP0225020A2 (en) | Peptides comprising, in sequence, units selected from the amino-acid residues 17 to 24 of ViP | |
| JPS6345398B2 (en) | ||
| US4299821A (en) | Tripeptides acting on the central nervous system and a process for the preparation thereof | |
| Li et al. | The Synthesis of L-Histidyl-L-phenylalanyl-L-ornithyl-L-tryptophyl-glycine and L-Histidyl-D-phenylalanyl-L-ornithyl-L-tryptophyl-glycine and their Melanocyte-stimulating Activity | |
| GB2109796A (en) | Anorexigenic tripeptides, process for the preparation thereof and pharmaceutical compositions containing them | |
| US3856770A (en) | Psychopharmacologically active tetra-, penta-, hexa-, and heptapeptides | |
| CA2173939C (en) | Oligopeptides derived from c-reactive protein fragments | |
| US3888838A (en) | Decapeptide having luteinizing hormone (lh)-and follicle stimulating hormone (fsh)-releasing activity, salts and compositions thereof, a process for preparing same, and intermediates therefor | |
| US4491541A (en) | Peptides | |
| US4636490A (en) | Novel peptidic derivatives inhibiting gastric secretion, process for preparing them and drugs containing them | |
| US3801561A (en) | Derivatives of salmon thyrocalcitonin | |
| US4111923A (en) | Octapeptides and methods for their production | |
| FR2595705A1 (en) | GONADOLIBERIN DERIVATIVES CONTAINING AROMATIC AMINOCARBOXYLIC ACID IN POSITION 6, PHARMACEUTICAL AND VETERINARY COMPOSITIONS CONTAINING SAME AND PROCESS FOR PREPARING THE SAME | |
| GB2130590A (en) | Peptides | |
| US4256736A (en) | Psychopharmacological peptides | |
| CZ278982B6 (en) | Peptide exhibiting immunomodulating activity, process of its preparation and pharmaceutical preparation in which it is comprised | |
| SE456345B (en) | LUTE INITIATION AND FOLLYCLE STIMULATING HORMONES RELEASE FACTOR ANALOGUES WITH HIGH GONADOTROPIC EFFECTS AND A PROCEDURE FOR PRODUCING THEREOF | |
| US4172130A (en) | α-AMINOACYL CONTAINING NEW PEPTIDES WITH GASTRIN EFFECTS AND A PROCESS FOR THE PREPARATION THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |